Literature DB >> 11788208

Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.

L Katherine Morrison1, Alex Harrison, Padma Krishnaswamy, Radmila Kazanegra, Paul Clopton, Alan Maisel.   

Abstract

OBJECTIVES: Since B-type natriuretic peptide (BNP) is secreted by the left ventricle (LV) in response to volume elevated LV pressure, we sought to assess whether a rapid assay for BNP levels could differentiate cardiac from pulmonary causes of dyspnea.
BACKGROUND: Differentiating congestive heart failure (CHF) from pulmonary causes of dyspnea is very important for patients presenting to the emergency department (ED) with acute dyspnea.
METHODS: B-natriuretic peptide levels were obtained in 321 patients presenting to the ED with acute dyspnea. Physicians were blinded to BNP levels and asked to give their probability of the patient having CHF and their final diagnosis. Two independent cardiologists were blinded to BNP levels and asked to review the data and evaluate which patients presented with heart failure. Patients with right heart failure from cor pulmonale were classified as having CHF.
RESULTS: Patients with CHF (n = 134) had BNP levels of 758.5 +/- 798 pg/ml, significantly higher than the group of patients with a final diagnosis of pulmonary disease (n = 85) whose BNP was 61 +/- 10 pg/ml. The area under the receiver operating curve, which plots sensitivity versus specificity for BNP levels in separating cardiac from pulmonary disease, was 0.96 (p < 0.001). A breakdown of patients with pulmonary disease revealed: chronic obstructive pulmonary disease (COPD): 54 +/- 71 pg/ml (n = 42); asthma: 27 +/- 40 pg/ml (n = 11); acute bronchitis: 44 +/- 112 pg/ml (n = 14); pneumonia: 55 +/- 76 pg/ml (n = 8); tuberculosis: 93 +/- 54 pg/ml (n = 2); lung cancer: 120 +/- 120 pg/ml (n = 4); and acute pulmonary embolism: 207 +/- 272 pg/ml (n = 3). In patients with a history of lung disease but whose current complaint of dyspnea was seen as due to CHF, BNP levels were 731 +/- 764 pg/ml (n = 54). The group with a history of CHF but with a current COPD diagnosis had a BNP of 47 +/- 23 pg/ml (n = 11).
CONCLUSIONS: Rapid testing of BNP in the ED should help differentiate pulmonary from cardiac etiologies of dyspnea.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788208     DOI: 10.1016/s0735-1097(01)01744-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  89 in total

1.  Correlation between NT proBNP and left ventricular ejection fraction in elderly patients presenting to emergency department with dyspnoea.

Authors:  Amulya C Belagavi; Medha Rao; Aslam Y Pillai; U S Srihari
Journal:  Indian Heart J       Date:  2012 May-Jun

2.  [Validity and usefulness of B-type natriuretic peptide (BNP) for early detection of left ventricular dysfunction in high-risk patients in primary care].

Authors:  José M Lobos Bejarano; Cristina Horrillo García; Ana I González-González; Angel Castellanos Rodríguez; Santiago Díaz Sánchez; Javier Castellanos Maroto; Ricardo Rodriguez-Barrientos; Miguel A García-Fernández
Journal:  Aten Primaria       Date:  2011-06-01       Impact factor: 1.137

3.  Comments on elevated cardiac troponin in patients with COPD.

Authors:  Aaron Joffe
Journal:  Intensive Care Med       Date:  2004-01-16       Impact factor: 17.440

Review 4.  Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides.

Authors:  R Senior; G Galasko; J V McMurray; J Mayet
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

Review 5.  Best evidence topic report. Brain natriuretic peptide as a potential marker of acute coronary syndromes.

Authors:  Richard Body; Catherine Roberts
Journal:  Emerg Med J       Date:  2006-05       Impact factor: 2.740

6.  Left ventricular assist device: a functional comparison with heart transplantation.

Authors:  R V Pruijsten; N de Jonge; J H Kirkels; C Klöpping; P A F M Doevendans; A Oosterom; H Kemperman; J R Lahpor
Journal:  Neth Heart J       Date:  2008-02       Impact factor: 2.380

Review 7.  Usefulness of lung ultrasound in the bedside distinction between pulmonary edema and exacerbation of COPD.

Authors:  Giovanni Volpicelli; Luciano Cardinale; Giorgio Garofalo; Andrea Veltri
Journal:  Emerg Radiol       Date:  2008-01-31

Review 8.  Biomarker guided therapy for heart failure: focus on natriuretic peptides.

Authors:  Kirkwood F Adams; G Michael Felker; Ghassan Fraij; J Herbert Patterson; Christopher M O'Connor
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

Review 9.  Overcoming gaps in the management of asthma in older patients: new insights.

Authors:  Pranoy Barua; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

10.  Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure.

Authors:  A S Androne; K Hryniewicz; R Goldsmith; A Arwady; S D Katz
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.